|1.||Karjalainen, Pasi P: 10 articles (03/2015 - 10/2006)|
|2.||Ylitalo, Antti: 9 articles (12/2013 - 10/2006)|
|3.||Nammas, Wail: 7 articles (03/2015 - 03/2012)|
|4.||Sia, Jussi: 7 articles (03/2015 - 08/2008)|
|5.||Niemelä, Matti: 7 articles (03/2015 - 08/2008)|
|6.||Airaksinen, Juhani K E: 6 articles (03/2015 - 10/2006)|
|7.||Nyman, Kai: 5 articles (03/2015 - 08/2008)|
|8.||Kervinen, Kari: 5 articles (11/2013 - 08/2008)|
|9.||Airaksinen, K E Juhani: 5 articles (09/2013 - 08/2008)|
|10.||Pietilä, Mikko: 4 articles (11/2013 - 01/2009)|
|1.||Acute Coronary Syndrome
12/01/2012 - "The titanium-nitride-oxide coated bio-active stent (BAS) has shown promising results in patients with acute coronary syndromes, but there is little long-term optical coherence tomography (OCT) data comparing BAS with DES. "
03/01/2015 - "The randomized comparison of titanium-nitride-oxide-coated bioactive stent with everolimus-eluting stent in acute coronary syndrome (BASE-ACS) trial demonstrated an outcome of the titanium-nitride-oxide coated bioactive stents (BASs) that was statistically noninferior to that of the everolimus-eluting stents (EESs) at 12-month follow-up, in patients presenting with acute coronary syndrome (ACS) who underwent early percutaneous coronary intervention. "
02/01/2015 - "TIDES-ACS Trial: comparison of titanium-nitride-oxide coated bio-active-stent to the drug (everolimus)-eluting stent in acute coronary syndrome. "
12/01/2013 - "In a post hoc analysis of the BASE-ACS trial, we sought to assess neointimal coverage and coronary flow reserve (CFR) 9 months after implantation of titanium-nitride-oxide-coated bioactive stents (BAS) versus everolimus-eluting stents (EES) in patients with acute coronary syndrome (ACS). "
12/01/2013 - "Neointimal coverage and vasodilator response to titanium-nitride-oxide-coated bioactive stents and everolimus-eluting stents in patients with acute coronary syndrome: insights from the BASE-ACS trial."
05/01/2010 - "Patients in the TiNOX-group had lower all-cause mortality and less myocardial infarction, but the difference was not statistically significant. "
07/01/2014 - "We performed a pooled analysis based on patient-level data from the TITAX-AMI and BASE-ACS trials to evaluate the outcome of titanium-nitride-oxide-coated bioactive stents vs drug-eluting stents in patients with ST-segment elevation myocardial infarction at 2-year follow-up. "
09/30/2013 - "Five-year clinical outcome of titanium-nitride-oxide-coated bioactive stents versus paclitaxel-eluting stents in patients with acute myocardial infarction: long-term follow-up from the TITAX AMI trial."
12/01/2012 - "Stent strut coverage of titanium-nitride-oxide coated stent compared to paclitaxel-eluting stent in acute myocardial infarction: TITAX-OCT study."
03/01/2012 - "The TITAX-AMI trial demonstrated a better clinical outcome of titanium-nitride-oxide-coated bioactive stents (BAS) as compared with paclitaxel-eluting stents (PES) in patients with acute myocardial infarction (MI) undergoing early percutaneous coronary intervention (PCI). "
|4.||Coronary Artery Disease (Coronary Atherosclerosis)
10/01/2006 - "The aim of this study was to compare clinical outcome of a stainless-steel stent coated with titanium nitride oxide (TITANOX) and a paclitaxel-eluting stent (PES) in routine clinical practice represented by two prospective registries including all patients with de novo coronary artery disease treated exclusively with a TITANOX stent (n = 201) or with a PES (n = 204) between May 2003 and November 2004 (63% of all PCI patients). "
05/24/2005 - "Stent coating with titanium-nitride-oxide has been shown to reduce neointimal hyperplasia in the porcine restenosis model. "
08/21/2001 - "Stent coating with titanium-nitride-oxide for reduction of neointimal hyperplasia."
08/21/2001 - "TiNOX coating significantly reduces neointimal hyperplasia in stainless steel stents. "
|3.||Stainless Steel (Steel, Stainless)
|7.||glucuronyl glucosamine glycan sulfate (Vessel)